HPC
GALT icon

HM Payson & Co’s Galectin Therapeutics GALT Stock Holding History

HM Payson & Co’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,252
Closed -$7K – 1119
2021
Q1 		$7K Hold
3,252
– – ﹤0.01% 905
2020
Q4 		$7K Hold
3,252
– – ﹤0.01% 896
2020
Q3 		$9K Hold
3,252
– – ﹤0.01% 843
2020
Q2 		$10K Hold
3,252
– – ﹤0.01% 745
2020
Q1 		$6K Hold
3,252
– – ﹤0.01% 790
2019
Q4 		$9K Hold
3,252
– – ﹤0.01% 811
2019
Q3 		$12K Hold
3,252
– – ﹤0.01% 795
2019
Q2 		$13K Buy
+3,252
New +$14.1K ﹤0.01% 785

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HM Payson & Co's GALT Position: Q2 2021 in Review

HM Payson & Co sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 3,252 shares — an estimated $7K sold.

HM Payson & Co first reported a position in GALT in Q2 2019 and held it in 8 quarters. The position peaked at $13K in Q2 2019. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

  • HM Payson & Co reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 3,252 Galectin Therapeutics shares in Q2 2021, an estimated $7K.
  • HM Payson & Co first reported a position in Galectin Therapeutics in Q2 2019 and held it in 8 quarters.
  • HM Payson & Co's Galectin Therapeutics position peaked at $13K in Q2 2019.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.